{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:05:50Z","timestamp":1785891950883,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emergence and spread of antiviral drug-resistant viruses have been a worldwide challenge and a great concern for patient care. We report A4 antibody specifically recognizing and binding to the mutant I223R\/H275Y neuraminidase and prove the applicability of A4 antibody for direct detection of antiviral multidrug-resistant viruses in various sensing platforms, including naked-eye detection, surface-enhanced Raman scattering-based immunoassay, and lateral flow system. The development of the A4 antibody enables fast, simple, and reliable point-of-care assays of antiviral multidrug-resistant influenza viruses. In addition to current influenza virus infection testing methods that do not provide information on the antiviral drug-resistance of the virus, diagnostic tests for antiviral multidrug-resistant viruses will improve clinical judgment in the treatment of influenza virus infections, avoid the unnecessary prescription of ineffective drugs, and improve current therapies.<\/jats:p>","DOI":"10.1038\/s41467-020-17246-w","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T10:05:38Z","timestamp":1594289138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of A4 antibody for detection of neuraminidase I223R\/H275Y-associated antiviral multidrug-resistant influenza virus"],"prefix":"10.1038","volume":"11","author":[{"given":"Kyeonghye","family":"Guk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Aa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul Gee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Nan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwangseo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongeun","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-6458","authenticated-orcid":false,"given":"Taejoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyung","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1969-321X","authenticated-orcid":false,"given":"Juyeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"17246_CR1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","volume":"363","author":"M Von Itzstein","year":"1993","unstructured":"Von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418\u2013423 (1993).","journal-title":"Nature"},{"key":"17246_CR2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","volume":"119","author":"CU Kim","year":"1997","unstructured":"Kim, C. U. et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681\u2013690 (1997).","journal-title":"J. Am. Chem. Soc."},{"key":"17246_CR3","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","volume":"360","author":"FS Dawood","year":"2009","unstructured":"Dawood, F. S., Jain, S., Fineli, L. & Shaw, M. W. Emergene of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360, 2605\u20132615 (2009).","journal-title":"N. Engl. J. Med."},{"key":"17246_CR4","first-page":"1700","volume":"385","author":"H Kelly","year":"2017","unstructured":"Kelly, H. & Cowling, B. J. Influenza: the rational use of oseltamivir. Lancet Infect. Dis. 385, 1700\u20131702 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"17246_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dki018","volume":"55","author":"P Ward","year":"2005","unstructured":"Ward, P., Small, I., Smith, J., Suter, P. & Dutkowski, R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55, 5\u201321 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"17246_CR6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1086\/596311","volume":"48","author":"I Stephenson","year":"2009","unstructured":"Stephenson, I. et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 48, 386\u2013389 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"17246_CR7","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa054512","volume":"353","author":"MD De Jong","year":"2005","unstructured":"De Jong, M. D. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med 353, 2667\u20132672 (2005).","journal-title":"N. Engl. J. Med"},{"key":"17246_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.13.05.08026-en","volume":"13","author":"A Lackenby","year":"2008","unstructured":"Lackenby, A. et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eur. Surveill. 13, 1\u20132 (2008).","journal-title":"Eur. Surveill."},{"key":"17246_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid1504.181280","volume":"15","author":"A Meijer","year":"2009","unstructured":"Meijer, A. et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007\u201308 season. Emerg. Infect. Dis. 15, 552\u2013560 (2009).","journal-title":"Emerg. Infect. Dis."},{"key":"17246_CR10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/JVI.02485-14","volume":"89","author":"YH Baek","year":"2015","unstructured":"Baek, Y. H. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. J. Virol. 89, 287\u2013299 (2015).","journal-title":"J. Virol."},{"key":"17246_CR11","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1003749","volume":"363","author":"E Van der Vries","year":"2010","unstructured":"Van der Vries, E., Stelma, F. F. & Boucher, C. A. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363, 1381\u20131382 (2010).","journal-title":"N. Engl. J. Med."},{"key":"17246_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3201\/eid1802.111466","volume":"18","author":"AD Storms","year":"2012","unstructured":"Storms, A. D. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg. Infect. Dis. 18, 308\u2013311 (2012).","journal-title":"Emerg. Infect. Dis."},{"key":"17246_CR13","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2165\/11531450-000000000-00000","volume":"69","author":"AC Hurt","year":"2009","unstructured":"Hurt, A. C., Holien, J. K., Parker, M. W. & Barr, I. G. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 69, 2523\u20132531 (2009).","journal-title":"Drugs"},{"key":"17246_CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3851\/IMP2067","volume":"17","author":"HT Nguyen","year":"2012","unstructured":"Nguyen, H. T., Fry, A. M. & Gubareva, L. V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17, 159\u2013173 (2012).","journal-title":"Antivir. Ther."},{"key":"17246_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcv.2013.01.009","volume":"57","author":"F Pozo","year":"2013","unstructured":"Pozo, F. et al. Community network of reference laboratories for human influenza in Europe. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J. Clin. Virol. 57, 5\u201312 (2013).","journal-title":"J. Clin. Virol."},{"key":"17246_CR16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.05994-11","volume":"56","author":"A Pizzorno","year":"2012","unstructured":"Pizzorno, A., Abed, Y., Bouhy, X., Beaulieu, E. & Mallett, C. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob. Agents Chemother. 56, 1208\u20131214 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"17246_CR17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","volume":"12","author":"AC Hurt","year":"2012","unstructured":"Hurt, A. C. et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12, 240\u2013248 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"17246_CR18","doi-asserted-by":"crossref","first-page":"e37095","DOI":"10.1371\/journal.pone.0037095","volume":"7","author":"J LeGoff","year":"2012","unstructured":"LeGoff, J. et al. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS ONE 7, e37095 (2012).","journal-title":"PLoS ONE"},{"key":"17246_CR19","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1039\/c3mb70253g","volume":"9","author":"H Tan","year":"2013","unstructured":"Tan, H., Wei, K., Bao, J. & Zhou, X. In silico study on multidrug resistance conferred by I223R\/H275Y double mutant neuraminidase. Mol. Biosyst. 9, 2764\u20132774 (2013).","journal-title":"Mol. Biosyst."},{"key":"17246_CR20","doi-asserted-by":"crossref","first-page":"e1002276","DOI":"10.1371\/journal.ppat.1002276","volume":"7","author":"E Van der Vries","year":"2011","unstructured":"Van der Vries, E., Veldhuis Kroeze, E. J., Stittelaar, K. J., Linster, M. & Van der Linden, A. Multidrug resistant 2009 A\/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog. 7, e1002276 (2011).","journal-title":"PLoS Pathog."},{"key":"17246_CR21","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","volume":"385","author":"J Dobson","year":"2015","unstructured":"Dobson, J., Whitley, R. J., Pocock, S. & Monto, A. S. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385, 1729\u20131737 (2015).","journal-title":"Lancet"},{"key":"17246_CR22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1086\/598513","volume":"48","author":"SA Harper","year":"2009","unstructured":"Harper, S. A. et al. Current approaches for diagnosis of influenza virus infections in humans. Clin. Infect. Dis. 48, 1003\u20131032 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"17246_CR23","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1128\/JVI.01424-10","volume":"84","author":"CW Seibert","year":"2010","unstructured":"Seibert, C. W. et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84, 11219\u201311226 (2010).","journal-title":"J. Virol."},{"key":"17246_CR24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.antiviral.2012.01.006","volume":"93","author":"HT Nguyen","year":"2012","unstructured":"Nguyen, H. T. et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antivir. Res. 93, 381\u2013386 (2012).","journal-title":"Antivir. Res."},{"key":"17246_CR25","doi-asserted-by":"crossref","first-page":"e21446","DOI":"10.1371\/journal.pone.0021446","volume":"6","author":"SY Tong","year":"2011","unstructured":"Tong, S. Y. et al. Rapid detection of the H275Y oseltamivir resistance mutation in influenza A\/H1N1 2009 by single base pair RT-PCR and high-resolution melting. PLoS ONE 6, e21446 (2011).","journal-title":"PLoS ONE"},{"key":"17246_CR26","doi-asserted-by":"crossref","first-page":"e1001022","DOI":"10.1371\/journal.ppat.1001022","volume":"6","author":"S Duan","year":"2010","unstructured":"Duan, S. et al. Oseltamivir-resistant pandemic H1N1\/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6, e1001022 (2010).","journal-title":"PLoS Pathog."},{"key":"17246_CR27","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1128\/AAC.02145-12","volume":"57","author":"P Yates","year":"2013","unstructured":"Yates, P., Mehta, N., Horton, J. & Tisdale, M. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob. Agents Chemother. 57, 1677\u20131384 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"17246_CR28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1128\/JCM.02611-15","volume":"54","author":"AS Whale","year":"2016","unstructured":"Whale, A. S. et al. Detection of rare drug resistance mutations by digital pcr in a human influenza A virus model system and clinical samples. J. Clin. Microbiol. 54, 392\u2013400 (2016).","journal-title":"J. Clin. Microbiol."},{"key":"17246_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/glycob\/10.2.121","volume":"10","author":"S M\u00fcller-Loennies","year":"2000","unstructured":"M\u00fcller-Loennies, S. et al. Characterization of high affinity monoclonal antibodies specific for chlamydial lipopolysaccharide. Glycobiology 10, 121\u2013130 (2000).","journal-title":"Glycobiology"},{"key":"17246_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.1065659","volume":"294","author":"D Baker","year":"2001","unstructured":"Baker, D. & Sali., A. Protein structure prediction and structural genomics. Science 294, 93\u201396 (2001).","journal-title":"Science"},{"key":"17246_CR31","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1021\/acs.chemmater.7b02932","volume":"29","author":"Y Yoo","year":"2017","unstructured":"Yoo, Y. et al. Surfactant-free vapor-phase synthesis of single-crystalline gold nanoplates for optimally bioactive surfaces. Chem. Mater. 29, 8747\u20138756 (2017).","journal-title":"Chem. Mater."},{"key":"17246_CR32","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.antiviral.2013.08.002","volume":"100","author":"M Kim","year":"2013","unstructured":"Kim, M. et al. Inhibition of influenza virus internalization by (-)-epigallocatechin-3-3gallate. Antivir. Res. 100, 460\u2013472 (2013).","journal-title":"Antivir. Res."},{"key":"17246_CR33","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1128\/JVI.07032-11","volume":"86","author":"E Vanderlinden","year":"2012","unstructured":"Vanderlinden, E. et al. Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin. J. Virol. 86, 9416\u20139431 (2012).","journal-title":"J. Virol."},{"key":"17246_CR34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.14348\/molcells.2017.0106","volume":"40","author":"S Kim","year":"2017","unstructured":"Kim, S. et al. Generation, diversity determination, and application to antibody selection of a human na\u00efve Fab library. Mol. Cells 40, 655\u2013666 (2017).","journal-title":"Mol. Cells"},{"key":"17246_CR35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0022-2836(91)90498-U","volume":"222","author":"JD Marks","year":"1991","unstructured":"Marks, J. D. et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581\u2013597 (1991).","journal-title":"J. Mol. Biol."},{"key":"17246_CR36","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1074\/jbc.M511165200","volume":"17","author":"SO Yoon","year":"2006","unstructured":"Yoon, S. O. et al. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 17, 6985\u20136992 (2006).","journal-title":"J. Biol. Chem."},{"key":"17246_CR37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","volume":"234","author":"A Sali","year":"1993","unstructured":"Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779\u2013815 (1993).","journal-title":"J. Mol. Biol."},{"key":"17246_CR38","doi-asserted-by":"crossref","first-page":"e33340","DOI":"10.1371\/journal.pone.0033340","volume":"7","author":"CM Yu","year":"2012","unstructured":"Yu, C. M. et al. Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface. PLoS ONE 7, e33340 (2012).","journal-title":"PLoS ONE"},{"key":"17246_CR39","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1110\/ps.9.9.1753","volume":"9","author":"A Fiser","year":"2000","unstructured":"Fiser, A., Do, R. K. & Sali, A. G. Modeling of loops in protein structures. Protein Sci. 9, 1753\u20131773 (2000).","journal-title":"Protein Sci."},{"key":"17246_CR40","doi-asserted-by":"crossref","first-page":"e1002914","DOI":"10.1371\/journal.ppat.1002914","volume":"8","author":"E Van Der Vries","year":"2012","unstructured":"Van Der Vries, E. et al. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog. 8, e1002914 (2012).","journal-title":"PLoS Pathog."},{"key":"17246_CR41","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","volume":"19","author":"GM Morris","year":"1998","unstructured":"Morris, G. M. et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639\u20131662 (1998).","journal-title":"J. Comput. Chem."},{"key":"17246_CR42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/protein\/4.8.903","volume":"4","author":"EL Mehler","year":"1991","unstructured":"Mehler, E. L. & Solmajer, T. Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng. 4, 903\u2013910 (1991).","journal-title":"Protein Eng."},{"key":"17246_CR43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/08927029308022161","volume":"10","author":"PFW Stouten","year":"1993","unstructured":"Stouten, P. F. W. et al. An effective solvation term based on atomic occupancies for use in protein simulations. Mol. Simul. 10, 97\u2013120 (1993).","journal-title":"Mol. Simul."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17246-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17246-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17246-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:16:35Z","timestamp":1723220195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17246-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17246"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17246-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"28 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3418"}}